DURECT CORP. DL-,001 (DC8A.MU)
Munich - Munich Delayed Price. Currency in EUR
Add to watchlist
At close: 08:01AM CEST
| Previous Close | 0.9850 |
| Open | 1.1600 |
| Bid | 1.1100 x N/A |
| Ask | 1.1400 x N/A |
| Day's Range | 1.1600 - 1.1600 |
| 52 Week Range | 0.4660 - 1.1800 |
| Volume | |
| Avg. Volume | 16 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireDURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
- GuruFocus.com
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
Amidst revenue decline and significant cash burn, Durect Corp reports promising clinical trial results and strategic FDA interactions.
© 2024 Yahoo. All rights reserved.